(Q29616300)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

review article

1 reference

title

Neuroinflammation in Parkinson's disease: a target for neuroprotection? (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Stéphane Hunot

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Hirsch EC

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

Hunot S

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

1 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

8

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

382-397

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

4

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inflammation and the degenerative diseases of aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Glutathione peroxidase, glial cells and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

gamma delta+ T cells are increased in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Alterations of T-lymphocyte populations in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Microglial activation and dopamine terminal loss in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Peripheral inflammatory biomarkers and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Genetic analysis of immunomodulating factors in sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Relation between the high production related allele of the interferon-gamma (IFN-gamma) gene and age at onset of idiopathic Parkinson's disease in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Microglial response to 6-hydroxydopamine-induced substantia nigra lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Mechanism of toxicity in rotenone models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Synuclein activates microglia in a model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Parkin deficiency increases vulnerability to inflammation-related nigral degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Oxidative modifications of alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Altered regulation of iron transport and storage in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Fas and Fas-L expression in Huntington's disease and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Clinical trials. Halt of Celebrex study threatens drug's future, other trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cardiovascular effects of the cyclooxygenase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The role of glial reaction and inflammation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Minocycline and neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Minocycline enhances MPTP toxicity to dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Rise and fall of minocycline in neuroprotection: need to promote publication of negative results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Smoking and Parkinson's disease: a dose-response relationship.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Smoking, nicotine and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

2-(Arylmethyl)-3-substituted quinuclidines as selective alpha 7 nicotinic receptor ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Purinergic mediated changes in Ca2+ mobilization and functional responses in microglia: effects of low levels of ATP.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Glatiramer acetate for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Amyloid-beta immunisation for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

The adult human brain in preclinical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970062-6

7 January 2021

10.1016/S1474-4422(09)70062-6

Identifiers

DOI

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

30 April 2017

Consolidated OpenCitations Corpus – April 2017

959460

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19296921%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

959460

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19296921

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

959460